Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAB BioAtla	$0.36 -0.4%	$0.38	$0.24 ▼ $2.53	$20.92M	0.9	530,581 shs	504,140 shs
CING Cingulate	$4.19 +5.0%	$4.55	$3.02 ▼ $11.88	$22.68M	-0.74	159,309 shs	131,694 shs
ELEV Elevation Oncology	$0.37	$0.37	$0.22 ▼ $3.09	$21.62M	1.48	1.18 million shs	N/A
VAXX Vaxxinity	$0.03 +200.0%	$0.01	$0.00 ▼ $0.10	$3.80M	-24.16	7,107 shs	173 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAB BioAtla	-0.39%	-3.13%	-10.91%	-8.67%	-81.15%
CING Cingulate	+5.01%	+3.71%	-24.78%	+14.48%	-61.91%
ELEV Elevation Oncology	0.00%	0.00%	-2.14%	+15.62%	-54.96%
VAXX Vaxxinity	0.00%	-30.23%	+29,900.00%	+29,900.00%	+200.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAB BioAtla	2.2866 of 5 stars	3.0	3.0	0.0	0.0	1.5	2.5	0.6
CING Cingulate	2.4467 of 5 stars	3.5	3.0	0.0	0.0	2.1	0.8	0.6
ELEV Elevation Oncology	1.3513 of 5 stars	3.0	0.0	0.0	0.0	0.6	1.7	0.6
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAB BioAtla	2.00	Hold	$5.00	1,303.71% Upside
CING Cingulate	3.00	Buy	$26.25	526.49% Upside
ELEV Elevation Oncology	2.00	Hold	$2.62	616.89% Upside
VAXX Vaxxinity	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VAXX, BCAB, ELEV, and CING Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$61.00 ➝ $62.00
8/13/2025	BCAB BioAtla	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
8/13/2025	BCAB BioAtla	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/8/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAB BioAtla	$11M	1.90	N/A	N/A	($0.29) per share	-1.23
CING Cingulate	N/A	N/A	N/A	N/A	$1.02 per share	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	$0.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAB BioAtla	-$69.78M	-$1.10	N/A	N/A	N/A	N/A	-1,177.18%	-137.51%	11/6/2025 (Estimated)
CING Cingulate	-$15.55M	-$4.10	N/A	N/A	N/A	N/A	-232.16%	-132.07%	11/6/2025 (Estimated)
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	11/4/2025 (Estimated)
VAXX Vaxxinity	-$56.93M	-$0.45	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest VAXX, BCAB, ELEV, and CING Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/19/2025	Q2 2025	CING Cingulate	-$0.82	-$1.09	-$0.27	-$1.09	N/A	N/A
8/7/2025	Q2 2025	BCAB BioAtla	-$0.29	-$0.31	-$0.02	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAB BioAtla	N/A	1.24	1.24
CING Cingulate	N/A	1.52	1.87
ELEV Elevation Oncology	0.67	19.40	19.40
VAXX Vaxxinity	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAB BioAtla	77.23%
CING Cingulate	41.31%
ELEV Elevation Oncology	83.70%
VAXX Vaxxinity	82.95%

Insider Ownership

Company	Insider Ownership
BCAB BioAtla	11.22%
CING Cingulate	5.27%
ELEV Elevation Oncology	8.10%
VAXX Vaxxinity	64.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAB BioAtla	60	58.72 million	52.13 million	Optionable
CING Cingulate	20	5.41 million	5.13 million	Not Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
VAXX Vaxxinity	90	126.75 million	45.55 million	Not Optionable

VAXX, BCAB, ELEV, and CING Headlines

Recent News About These Companies

Brain health

October 24, 2024 | newsweek.comN

Treatment Trials in Alzheimer's Disease

September 30, 2024 | msn.com

Is Vaxxinity Inc (VAXX) Stock a Good Investment?

September 19, 2024 | aaii.comA

Congress makes $4.5 trading stocks in a day; Here's the biggest winners

July 4, 2024 | finbold.comF

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

June 20, 2024 | globenewswire.com

Why Is Vaxxinity (VAXX) Stock Up 39% Today?

May 3, 2024 | investorplace.com

Why Is Vaxxinity (VAXX) Stock Down 58% Today?

April 22, 2024 | investorplace.com

Vaxxinity Plans to Delist Shares From Nasdaq

April 19, 2024 | marketwatch.com

Vaxxinity Issues Shareholder Letter

April 19, 2024 | globenewswire.com

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

April 19, 2024 | globenewswire.com

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

March 28, 2024 | globenewswire.com

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

March 27, 2024 | investorplace.com

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

March 27, 2024 | globenewswire.com

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

March 7, 2024 | globenewswire.com

Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels

February 15, 2024 | finance.yahoo.com

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 15, 2024 | finance.yahoo.com

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 15, 2024 | globenewswire.com

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

February 13, 2024 | finance.yahoo.com

Vaxxinity, UF Join Forces Against Neurodegenerative Diseases

January 30, 2024 | finance.yahoo.com

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

January 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VAXX, BCAB, ELEV, and CING Company Descriptions

BioAtla NASDAQ:BCAB

$0.36 0.00 (-0.39%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.37 +0.01 (+3.03%)

As of 08/22/2025 07:28 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Cingulate NASDAQ:CING

$4.19 +0.20 (+5.01%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.03 -0.16 (-3.82%)

As of 08/22/2025 07:28 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)

As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Vaxxinity NASDAQ:VAXX

$0.03 +0.02 (+200.00%)

As of 08/22/2025 10:30 AM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time